The TBC1D24 gene is associated with early infantile epileptic encephalopathy type 16 (EIEE16), a severe neurological condition that manifests early in infancy. This condition is characterized by frequent seizures that are resistant to treatment, developmental delay, and sometimes additional neurological symptoms. The TBC1D24 gene plays a crucial role in brain development and function, and mutations in this gene are known to disrupt these processes, leading to the symptoms observed in EIEE16.
To diagnose this condition, genetic testing is essential. DNA Labs UAE offers a specific genetic test targeting the TBC1D24 gene to confirm the presence of mutations that cause early infantile epileptic encephalopathy type 16. This test is crucial for the accurate diagnosis of EIEE16, enabling appropriate management and treatment strategies to be implemented for affected individuals. The cost of the TBC1D24 gene test at DNA Labs UAE is 4400 AED.
This test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing the TBC1D24 gene for any mutations. The results can provide valuable information for families regarding prognosis, potential treatment options, and the risk of recurrence in future pregnancies. It is also a step forward in understanding the genetic basis of the condition, contributing to ongoing research and potential future therapies.
The GNAO1 gene is crucial for proper brain function and development. Mutations in this gene can lead to a rare but severe condition known as Early Infantile Epileptic Encephalopathy Type 17 (EIEE17). This condition is characterized by frequent seizures that begin in the first few months of life, developmental delays, and other neurological issues. Genetic testing for mutations in the GNAO1 gene is essential for diagnosing EIEE17, guiding treatment options, and offering genetic counseling for families.
DNA Labs UAE offers a comprehensive genetic test to detect mutations in the GNAO1 gene, aiding in the diagnosis of Early Infantile Epileptic Encephalopathy Type 17. The test is a crucial step for families seeking answers about this challenging condition. The cost of the test is 4400 AED, reflecting the specialized analysis required to accurately identify the presence of mutations in the GNAO1 gene. By opting for this test, families can gain valuable insights into their child's condition, enabling better management and care strategies tailored to their specific needs.
The GABRA1 gene is associated with early infantile epileptic encephalopathy type 19 (EIEE19), a severe form of epilepsy that emerges in infancy. This condition is characterized by frequent seizures and significant developmental delays, affecting both cognitive and motor skills. The GABRA1 gene plays a crucial role in the functioning of GABA receptors, which are essential for inhibiting nerve transmission in the brain, thus preventing excessive neuronal activity that can lead to seizures.
Given the critical nature of accurately diagnosing EIEE19 for effective management and treatment, genetic testing for mutations in the GABRA1 gene is a valuable diagnostic tool. DNA Labs UAE offers a comprehensive genetic test specifically designed to identify mutations in the GABRA1 gene that are linked to early infantile epileptic encephalopathy type 19. The test is priced at 4400 AED and involves analyzing the patient's DNA to detect any genetic alterations that may contribute to the condition.
Conducting this test can provide crucial information for families and healthcare providers, enabling them to understand the genetic underpinnings of the disorder, anticipate its progression, and tailor treatment plans accordingly. It is an essential step for those affected by or at risk of EIEE19, offering hope for better management of this challenging condition.
The CDKL5 gene early infantile epileptic encephalopathy type 2 genetic test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the CDKL5 gene. This gene is crucial for normal brain development and function. Mutations in the CDKL5 gene are associated with early infantile epileptic encephalopathy type 2 (EIEE2), a severe neurological condition that manifests in the first few months of life with frequent seizures, developmental delays, and, in some cases, features of autism spectrum disorders. The test, priced at 4400 AED, involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory to detect any abnormalities in the CDKL5 gene. This genetic testing is essential for the accurate diagnosis and management of the condition, allowing for tailored treatment plans and support for affected individuals and their families.
The PIGA gene test for early infantile epileptic encephalopathy type 20 (EIEE20) is a specialized genetic examination designed to identify mutations in the PIGA gene, which are associated with this severe neurological condition. EIEE20 is characterized by early onset of frequent seizures, developmental delay, and various other neurological impairments. The test aims to provide a definitive diagnosis by analyzing the patient's DNA for specific genetic abnormalities within the PIGA gene that are known to cause the disorder.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test offers families and physicians critical information that can guide treatment decisions and prognosis. Understanding the genetic underpinnings of the condition can also be beneficial for genetic counseling, particularly for families considering future pregnancies.
The cost of the PIGA gene test for EIEE20 at DNA Labs UAE is 4400 AED. This price reflects the sophisticated technology and expertise required to accurately identify mutations in the PIGA gene. For families facing the challenges of EIEE20, this test represents a crucial step towards a clearer understanding of the condition and the potential for targeted therapeutic strategies.
The NECAP1 gene is associated with a rare neurological condition known as Early Infantile Epileptic Encephalopathy Type 21 (EIEE21). This condition is characterized by severe seizures that begin in the first few months of life, along with developmental delays and other possible neurological abnormalities. The NECAP1 gene plays a crucial role in brain development and function, and mutations in this gene can lead to the symptoms observed in EIEE21.
To diagnose this condition, a genetic test targeting the NECAP1 gene can be performed. This test is crucial for confirming the diagnosis, understanding the condition's progression, and aiding in the management and treatment planning for affected individuals. It involves analyzing the DNA to identify mutations in the NECAP1 gene that are known to cause EIEE21.
In the United Arab Emirates, this specific genetic test can be conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing services. The cost of the NECAP1 gene test for Early Infantile Epileptic Encephalopathy Type 21 is 4400 AED. This test is significant for families with a history of the condition or for infants showing symptoms associated with EIEE21, as it provides a definitive diagnosis and can guide further medical and therapeutic interventions.
The DOCK7 gene is associated with early infantile epileptic encephalopathy type 23 (EIEE23), a severe neurological disorder that typically manifests in the early stages of infancy. This condition is characterized by frequent seizures that are resistant to treatment, along with developmental delays and other potential neurological issues. The DOCK7 gene plays a crucial role in brain development and function, and mutations in this gene can disrupt normal neurological processes, leading to the symptoms observed in EIEE23.
To diagnose this condition accurately, genetic testing for mutations in the DOCK7 gene is essential. DNA Labs UAE offers a comprehensive genetic test specifically designed to identify mutations in the DOCK7 gene that are associated with early infantile epileptic encephalopathy type 23. This test is a critical tool for clinicians in diagnosing the condition, allowing for a better understanding of the prognosis and informing treatment strategies.
The cost of the DOCK7 gene test at DNA Labs UAE is 4400 AED. This investment includes the collection of a DNA sample, usually through a blood draw or cheek swab, and the subsequent analysis of the DOCK7 gene for any mutations. The results from this test can provide invaluable insights for families and healthcare providers, guiding them towards appropriate care and support for affected individuals.
Overall, the DOCK7 gene test offered by DNA Labs UAE is a specialized diagnostic tool that plays a pivotal role in identifying early infantile epileptic encephalopathy type 23, facilitating early intervention and tailored management plans for patients with this challenging condition.
The HCN1 gene plays a crucial role in the development and function of the brain. Mutations in this gene have been associated with early infantile epileptic encephalopathy type 24 (EIEE24), a severe form of epilepsy that manifests in the first few months of life. This condition is characterized by frequent seizures, developmental delays, and other neurological issues. Given the serious nature of EIEE24, early diagnosis is essential for managing symptoms and improving the quality of life for affected individuals.
DNA Labs UAE offers a genetic test specifically designed to detect mutations in the HCN1 gene. This test is a vital tool for diagnosing EIEE24, allowing for targeted treatment plans and genetic counseling for families. The process involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of mutations in the HCN1 gene.
The cost of the HCN1 gene test at DNA Labs UAE is 4400 AED. Although the price may seem high, the test provides invaluable information for the management of EIEE24, potentially leading to better outcomes for affected infants. It is recommended for families with a history of this condition or those whose infants show symptoms suggestive of EIEE24.
The "ADCY5 Gene Dyskinesia Familial with Facial Myokymia Genetic Test" is a specialized diagnostic tool designed to identify mutations in the ADCY5 gene, which are linked to a rare genetic disorder. This condition is characterized by dyskinesia—a disorder resulting in involuntary, erratic muscle movements—and facial myokymia, which involves continuous, rapid twitching of the facial muscles. These symptoms can significantly impact the quality of life, making accurate diagnosis crucial for management and treatment planning.
The test is conducted at DNA Labs UAE, a leading facility in genetic testing, ensuring high accuracy and reliability of results. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the sophisticated technology employed. By pinpointing the specific genetic alterations in the ADCY5 gene, this test enables healthcare professionals to confirm a diagnosis of ADCY5-related dyskinesia, facilitating tailored treatment approaches and genetic counseling for affected individuals and their families.
The PDE10A gene dyskinesia limb and orofacial infantile-onset genetic test is a specialized diagnostic tool aimed at identifying mutations in the PDE10A gene, which have been associated with early-onset movement disorders affecting the limbs and orofacial regions. This condition is characterized by involuntary muscle contractions leading to abnormal postures and movements, significantly impacting the quality of life from a very young age. The test is particularly relevant for individuals displaying symptoms of dyskinesia without a clear diagnosis, offering insights that can guide treatment and management strategies.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing the genetic material for specific mutations in the PDE10A gene. The cost of the test is 4400 AED, reflecting the intricate processes and advanced technology employed to achieve accurate and reliable results. By identifying the genetic underpinnings of the disorder, this test not only facilitates a better understanding of the individual's condition but also aids in the exploration of potential genetic counseling for families, providing them with valuable information regarding the inheritance patterns and risks for future offspring.
